EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings

Amrit S Gonugunta, Asad Haider, Virginia Mohlere, Mahmoud Aljurf, Shahrukh Hashmi, Muhammad Bilal Abid iD

Advances in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/ah/4529571 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Hematology, online erschienen am 07.05.2026. Verfasst von Amrit S Gonugunta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA, uth.edu. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies (BsAbs) are novel antitumor agents that simultaneously engage tumor‐associated antigens with CD3 on endogenous effector T cells, leading to cancer cell death. The immune‐mediated toxicity rates associated with BsAbs are considerably lower than those seen with CAR T‐cell therapy. Hence, widespread utilization of BsAb products in outpatient and community settings will allow greater and more homogeneous access and thus improve patient outcomes. In this review, we discuss the unique toxicities associated with BsAbs currently approved by the U.S. Food and Drug Administration and provide a disease‐agnostic framework for the safe community administration of BsAb therapy. With academic, community, and industrial partnerships, broader deployment of BsAbs could be streamlined. Education, provision of in‐services, leveraging protocols and experiences, and development of templates and guidelines will make this transition smoother and allow every patient in need of BsAbs to receive timely access to these survival‐prolonging therapies.

Schlagwörter

Stichwörter der Autor:innen

BiTEsBsAbsCAR-T therapyCRSICANScommunity practiceinfectionsoutpatienttoxicities

Autor:innen und Institutionen

  • Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA, uth.edu.
  • Division of Hematology/Oncology, The University of Texas Health Science Center, Houston, Texas, USA, uth.edu.
  • Oncology Center, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia, co.bydgoszcz.pl.
  • Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE, ssmcabudhabi.ae.
  • Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA, mayo.edu.
  • College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE, kustar.ac.ae.

ORCID-Profile: Muhammad Bilal Abid

Zitieren

APA

Gonugunta, A. S., Haider, A., Mohlere, V., Aljurf, M., Hashmi, S., & Abid, M. B. (2026). Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings. Advances in Hematology, 2026(1). https://doi.org/10.1155/ah/4529571

Vancouver

Gonugunta AS, Haider A, Mohlere V, Aljurf M, Hashmi S, Abid MB. Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings. Advances in Hematology. 2026;2026(1). doi:10.1155/ah/4529571

BibTeX
@article{Gonugunta2026,
  author = {Gonugunta, Amrit S and Haider, Asad and Mohlere, Virginia and Aljurf, Mahmoud and Hashmi, Shahrukh and Abid, Muhammad Bilal},
  title = {Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings},
  journal = {Advances in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ah/4529571}
}
Kostenlos starten →